Showing results (51-60 of 63) with videos related to
Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthaseJulie L Eiseman, Clive Brown-Proctor, Paul E Kinahan, et al.Journal of Liposome Research|June 10, 2010
Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor modelsWilliam C Zamboni, Julie L Eiseman, Sandra Strychor, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatinWilliam C Zamboni, Anne C Gervais, Merrill J Egorin, et al.Cancer Chemotherapy and Pharmacology|March 18, 2015
Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogsMiguel Muzzio, Shu-Chieh Hu, Julianne L Holleran, et al.Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.Cancer Chemotherapy and Pharmacology|December 16, 2003
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanomaWilliam C Zamboni, Anne C Gervais, Merrill J Egorin, et al.Cancer Chemotherapy and Pharmacology|January 9, 2015
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridineEdward M Newman, Robert J Morgan, Shivaani Kummar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancersRamesh K Ramanathan, Merrill J Egorin, Julie L Eiseman, et al.Cancer Chemotherapy and Pharmacology|May 6, 2010
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in miceJan H Beumer, Julie L Eiseman, Judith A Gilbert, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersRamesh K Ramanathan, Donald L Trump, Julie L Eiseman, et al.Pageof 7